XML 69 R50.htm IDEA: XBRL DOCUMENT v3.25.0.1
QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)
 12 Months Ended
Dec. 31, 2024
Quarterly Financial Information Disclosure [Abstract]  
Quarterly Financial Results and Market for Company's Stock The results of operations of any quarter are not necessarily indicative of the results that may be expected for any future period.
2024
(in millions, except per share data)First
Quarter
Second Quarter2
Third
Quarter
Fourth Quarter3
Full Year 1
Net sales$2,490 $2,694 $2,699 $2,753 $10,636 
Gross margin961 1,031 1,033 959 3,984 
Income (loss) from continuing operations6 95 61 (488)(326)
Income (loss) from discontinued operations33 (406)83 (22)(312)
Net income (loss)39 (311)144 (510)(638)
Net income (loss) attributable to Baxter stockholders37 (314)140 (512)(649)
Income (loss) from continuing operations per common share
Basic$0.01 $0.19 $0.12 $(0.95)$(0.64)
Diluted$0.01 $0.19 $0.12 $(0.95)$(0.64)
Income (loss) from discontinued operations per common share
Basic$0.06 $(0.81)$0.15 $(0.05)$(0.63)
Diluted$0.06 $(0.81)$0.15 $(0.05)$(0.63)
Net Income (loss) per common share
Basic$0.07 $(0.62)$0.27 $(1.00)$(1.27)
Diluted$0.07 $(0.62)$0.27 $(1.00)$(1.27)

2023
(in millions, except per share data)First
Quarter
Second Quarter4
Third
Quarter5
Fourth Quarter
Full Year 1
Net sales$2,441 $2,591 $2,599 $2,729 $10,360 
Gross margin964 1,030 1,056 1,100 4,150 
Income (loss) from continuing operations(48)(27)37 219 181 
Income from discontinued operations93 (112)2,474 27 2,482 
Net income (loss)45 (139)2,511 246 2,663 
Net income (loss) attributable to Baxter stockholders44 (141)2,508 245 2,656 
Income (loss) from continuing operations per common share
Basic$(0.10)$(0.05)$0.07 $0.43 $0.36 
Diluted$(0.10)$(0.05)$0.07 $0.43 $0.36 
Income from discontinued operations per common share
Basic$0.19 $(0.23)$4.88 $0.05 $4.89 
Diluted$0.19 $(0.23)$4.86 $0.05 $4.87 
Net Income (loss) per common share
Basic$0.09 $(0.28)$4.95 $0.48 $5.25 
Diluted$0.09 $(0.28)$4.93 $0.48 $5.23 
1The sum of per share amounts for quarterly periods may not equal full year amounts due to rounding.
2Our results from discontinued operations for the quarter ended June 30, 2024 included a $430 million charge related to a goodwill impairment of our Chronic Therapies reporting unit within our Kidney Care segment.
3Our results from continuing operations for the fourth quarter ended December 31, 2024 included a $425 million charge related to a goodwill impairment of our Front Line Care reporting unit within our Healthcare Systems & Technologies segment.
4Our results from discontinued operations for the quarter ended June 30, 2023 included $243 million of long-lived asset impairment charges resulting from our decision to cease production at one of our dialyzer manufacturing facilities.
5Our results from discontinued operations for the quarter ended September 30, 2023 included a gain of $2.88 billion from the sale of our BPS business, partially offset by $267 million of long-lived asset impairment charges related to our the hemodialysis business of our former Kidney Care segment.